Metabolic and Cardiovascular Outcomes
Cross-source consensus on Metabolic and Cardiovascular Outcomes from 1 sources and 5 claims.
1 sources · 5 claims
Benefits
Highlighted claims
- Semaglutide improved glycemic markers compared with placebo. — Semaglutide versus placebo in individuals with poor weight loss after bariatric surgery: a double-blinded, randomized, placebo-controlled trial
- Total cholesterol and triglycerides improved with semaglutide relative to placebo. — Semaglutide versus placebo in individuals with poor weight loss after bariatric surgery: a double-blinded, randomized, placebo-controlled trial
- Blood pressure changes favored semaglutide but were not statistically significant in the full intention-to-treat analysis. — Semaglutide versus placebo in individuals with poor weight loss after bariatric surgery: a double-blinded, randomized, placebo-controlled trial
- High-sensitivity C-reactive protein did not differ significantly between groups. — Semaglutide versus placebo in individuals with poor weight loss after bariatric surgery: a double-blinded, randomized, placebo-controlled trial
- HbA1c reductions were also observed among participants with prediabetes and type 2 diabetes, but subgroup sample sizes were small. — Semaglutide versus placebo in individuals with poor weight loss after bariatric surgery: a double-blinded, randomized, placebo-controlled trial